Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial
Pieter Sonneveld, Meletios A Dimopoulos, Meral Beksaç, Bronno van der Holt, Francesca Gay, Heinz Ludwig, Sonja Zweegman, Vladimír Maisnar, Maria Teresa Petrucci, Paolo Corradini, Fabrizio Patriarca, Angelo Belotti, Micol Quaresima, Mariella Grasso, Massimo Offidani, Laura París, Anna Marina Liberati, Markus Hansson, Heleen Visser-Wisselaar, Giulia Fumero, Renato Zambello, Paula F. Ypma, Anna Pascarella, Niels Frost Andersen, Alexandra Croockewit, Mario Boccadoro, Michèle Cavo (2024). Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-197908.
Article24 days agoAddition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Meletios A Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, Sebastian Grosicki, Michèle Cavo, Meral Beksaç, Wojciech Legieć, Anna Marina Liberati, Hartmut Goldschmidt, Andrew R. Belch, Hila Magen, Alessandra Larocca, Jacob P. Laubach, Maria Teresa Petrucci, Donna Reece, Darrell White, María‐Victoria Mateos, Ivan Špıčka, Mihaela Lazaroiu, Jesús G. Berdeja, Jonathan L. Kaufman, Ying‐Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Meletios A Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, Sebastian Grosicki, Michèle Cavo, Meral Beksaç, Wojciech Legieć, Anna Marina Liberati, Hartmut Goldschmidt, Andrew R. Belch, Hila Magen, Alessandra Larocca, Jacob P. Laubach, Maria Teresa Petrucci, Donna Reece, Darrell White, María‐Victoria Mateos, Ivan Špıčka, Mihaela Lazaroiu, Jesús G. Berdeja, Jonathan L. Kaufman, Ying‐Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Irwindeep Sandhu, Monika Podhorecka, Antonio Palumbo, Adi Shacham‐Abulafia, Iuliana Vaxman, Ofer Shpilberg, Britta Besemer, Maurizio Martelli, Roberto Foà, Paolo de Fabritiis, Tommaso Caravita di Toritto, Emanuil Gheorghita, Albert Oriol, Philip Rowlings, Angelucci Emanuele, Angelo Michele Carella, Massimo Offidani, Joan Bladé, Luis Felipe Casado, Heather Oakervee, Victoria Panelli, Luís Meza, Thomas Kühr, Miguel Granell, Don Benson, Rajesh Nair, Viran Holden, J. N. Reeves, Richard Eek, Patricia Walker, John Catalano, András Rosta, Ewa Lech‐Marańda, Christy Samaras, Tony Reiman, Robert Weaver, Péter Ács, Andrew Grigg, Bernard De Prijck, Martha Louzada, Leonard Minuk, Michaël Sébag, Martine Klausmann, Manfred Welslau, Andrzej Hellmann, Catalin Danaı̈la, Pamela S. Becker, William Bensinger (2022). Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. , 9(6), DOI: https://doi.org/10.1016/s2352-3026(22)00103-x.
Article24 days agoAddition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Meletios A Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, Sebastian Grosicki, Michèle Cavo, Meral Beksaç, Wojciech Legieć, Anna Marina Liberati, Hartmut Goldschmidt, Andrew R. Belch, Hila Magen, Alessandra Larocca, Jacob P. Laubach, Maria Teresa Petrucci, Donna Reece, Darrell White, María‐Victoria Mateos, Ivan Špıčka, Mihaela Lazaroiu, Jesús G. Berdeja, Jonathan L. Kaufman, Ying‐Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Meletios A Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, Sebastian Grosicki, Michèle Cavo, Meral Beksaç, Wojciech Legieć, Anna Marina Liberati, Hartmut Goldschmidt, Andrew R. Belch, Hila Magen, Alessandra Larocca, Jacob P. Laubach, Maria Teresa Petrucci, Donna Reece, Darrell White, María‐Victoria Mateos, Ivan Špıčka, Mihaela Lazaroiu, Jesús G. Berdeja, Jonathan L. Kaufman, Ying‐Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Irwindeep Sandhu, Monika Podhorecka, Antonio Palumbo, Adi Shacham‐Abulafia, Iuliana Vaxman, Ofer Shpilberg, Britta Besemer, Maurizio Martelli, Roberto Foà, Paolo de Fabritiis, Tommaso Caravita di Toritto, Emanuil Gheorghita, Albert Oriol, Philip Rowlings, Angelucci Emanuele, Angelo Michele Carella, Massimo Offidani, Joan Bladé, Luis Felipe Casado, Heather Oakervee, Victoria Panelli, Luís Meza, Thomas Kühr, Miguel Granell, Don Benson, Rajesh Nair, Viran Holden, J. N. Reeves, Richard Eek, Patricia Walker, John Catalano, András Rosta, Ewa Lech‐Marańda, Christy Samaras, Tony Reiman, Robert Weaver, Péter Ács, Andrew Grigg, Bernard De Prijck, Martha Louzada, Leonard Minuk, Michaël Sébag, Martine Klausmann, Manfred Welslau, Andrzej Hellmann, Catalin Danaı̈la, Pamela S. Becker, William Bensinger (2022). Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. , 9(6), DOI: https://doi.org/10.1016/s2352-3026(22)00103-x.
Article24 days agoDaratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study
María‐Victoria Mateos, Jesús F. San Miguel, Michèle Cavo, Joan Bladé Creixenti, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Luděk Pour, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung‐Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Meletios A Dimopoulos (2022). Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study. , 140(Supplement 1), DOI: https://doi.org/10.1182/blood-2022-163347.
Article24 days agoDaratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
María‐Victoria Mateos, Meletios A Dimopoulos, Michèle Cavo, Kenshi Suzuki, Stefan Knop, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Luděk Pour, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Sung‐Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Shinsuke Iida, Joan Bladé, Jon Ukropec, Huiling Pei, Rian Van Rampelbergh, Anupa Kudva, Ming Qi, Jesús F. San Miguel (2021). Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. , 21(11), DOI: https://doi.org/10.1016/j.clml.2021.06.005.
Article24 days ago